Fig. 1: IL33 expression correlates with TLS transcriptional signatures in human tumours.
From: IL-33-activated ILC2s induce tertiary lymphoid structures in pancreatic cancer
a,b, Unbiased correlation of bulk tumour mRNA gene expression to TLS transcriptional signatures (TLS signatures 1 (ref. 4), 2 (ref. 7) and 3 (ref. 8)) in human PDAC (a, top). Correlation of bulk tumour IL33 mRNA expression to TLS transcriptional signatures and LTB in human PDAC (a, bottom) and human tumours (TLS signature 1; b). c,d, Immunohistochemistry (c, left) and immunofluorescence (c, right), and the immunofluorescence-quantified frequency of bulk IL-33+ cells (c) and IL-33+CD45+ cells (d), and association with survival (c and d) in human PDAC. The dotted red line in c shows the putative TLS. Adj. panc., adjacent pancreatic tissue; HR, hazard ratio. n represents the number of tumours (a–c) or patients (survival; c and d). High and low (in the survival plots in c and d) represent ≥ (high) or < (low) the median frequency of the cohort. Horizontal bars in dot plots indicate the median (c, d). P values were calculated using two-sided Pearson correlation (a and b), two-tailed Mann–Whitney U-test (c (left) and d (left and middle)) and two-sided log-rank test (c (right) and d (right)). For c, scale bars, 20 μm (left) and 50 μm (right).
